MedTrace Logo

Depemokimab as an Extended treatmeNt Duration Biologic in Adults With Chronic Obstructive Pulmonary Disease (COPD) and Type 2 Inflammation (ENDURA-2)

NCT06961214 · Status: RECRUITING · Phase: PHASE3 · Type: INTERVENTIONAL · Enrollment: 960

Last updated 2026-04-09

No results posted yet for this study

Summary

Depemokimab is being developed as a treatment for individuals with moderate to severe COPD. The aim of this study is to assess the efficacy and safety of depemokimab compared as an add-on medicine in participants with uncontrolled moderate to severe COPD with type 2 inflammation.

Conditions

  • Pulmonary Disease, Chronic Obstructive

Interventions

DRUG

Depemokimab

Depemokimab as a sterile liquid formulation will be administered.

DRUG

Placebo

Placebo as a sterile 0.9 percent (%) sodium chloride solution will be administered

Sponsors & Collaborators

Principal Investigators

  • GSK Clinical Trials · GlaxoSmithKline

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
QUADRUPLE
Model
PARALLEL

Eligibility

Min Age
40 Years
Max Age
80 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2025-06-23
Primary Completion
2029-08-21
Completion
2029-08-21
FDA Drug
Yes

Countries

  • United States
  • Argentina
  • Australia
  • Austria
  • Bulgaria
  • Czechia
  • Germany
  • Greece
  • Israel
  • Italy
  • Latvia
  • New Zealand
  • Romania
  • South Korea
  • United Kingdom

Study Locations

More Related Trials

Entities

Drugs
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT06961214 on ClinicalTrials.gov